Program Information

This symposium is not part of the ATC official educational program and the sessions and content are not endorsed by ATC.

Monday, June 3, 2019
12:45 PM – 1:00 PM

Panel-Based Faculty Discussions
1:00 PM – 2:15 PM

Sheraton Boston Hotel
Grand Ballroom
39 Dalton Street
Boston, MA 02199

Join us for a spirited clinical case-based discussion amongst world-renowned experts. Ask your challenging questions about cytomegalovirus (CMV) and antibody-mediated rejection (AMR) in solid organ transplant (SOT) patients and learn about emerging therapies for improved patient outcomes.


12:45 PM – 1:00 PM
Lunch and Registration
1:00 PM – 1:10 PM
Opening Remarks, Introductions
Raymund R. Razonable, MD
1:10 PM – 1:25 PM
Patient Case 1: CMV
Late Onset CMV Disease
Raymund R. Razonable, MD and Full Panel
1:25 PM – 1:30 PM
Audience Q&A
All Faculty
1:30 PM – 1:45 PM
Patient Case 2: CMV
Rising CMV Viral Load on Antiviral Therapy
Ajit P. Limaye, MD and Full Panel
1:45 PM – 1:50 PM
Audience Q&A
All Faculty
1:50 PM – 2:05 PM
Patient Case 3: AMR
AMR in a Renal Transplant Patient
Arjang (Aji) Djamali, MD, MS, FASN and Full Panel
2:05 PM – 2:15 PM
Audience Q&A, Closing Remarks
All Faculty


Raymund R. Razonable, MD (Chair)
Professor, Medicine
Vice Chair, Division of Infectious Diseases
Department of Internal Medicine
Mayo Clinic
Rochester, MN
Arjang (Aji) Djamali, MD, MS, FASN
Professor, Medicine and Surgery
Head, Nephrology Division
Department of Medicine
University of Wisconsin School of Medicine and Public Health
Madison, WI
Ajit P. Limaye, MD
Professor, Medicine & Laboratory Medicine
University of Washington
Seattle, WA

Clinicians who manage cytomegalovirus (CMV) infection and/or antibody-mediated rejection (AMR) in patients who undergo solid organ transplant (SOT).

After engaging in this activity, transplant clinicians will be able to:

  • Fully implement early cytomegalovirus (CMV) prophylaxis and treatment in transplant patients
  • Manage CMV treatments in transplant patients based on viral load, side effect profile, and consideration of antiviral resistance
  • Identify early complement blockade as a strategy in the prevention and treatment of antibody-mediated rejection (AMR)
  • Provide aggressive treatment of AMR in order to prevent kidney damage and graft loss

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is jointly provided by RMEI Medical Education, LLC and AKH Inc., Advancing Knowledge in Healthcare.

This symposium is supported by an independent educational grant from Shire, now part of Takeda.

Statements of credit will be awarded based on the participant’s attendance, participation in the pre/post-test, and submission of the activity evaluation form. A statement of credit will be available upon completion of an evaluation/claimed credit form. If you have questions about this CME activity, please contact AKH Inc. at

It is the policy of AKH Inc., Advancing Knowledge in Healthcare and RMEI Medical Education, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by RMEI and AKH prior to accreditation of the activity and may include any of, or a combination of, the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence supports the recommendation; moderator review; and peer review. AKH planners and reviewers have no relevant financial relationships to disclose.

There is no fee for this educational activity.


Event staff will be glad to assist you with any special needs (physical, dietary, etc.). Please contact RMEI Medical Education, LLC prior to the live event at (866) 770-RMEI.

Please contact Nicole Fortune at if you have any questions.

Facebook  Twitter

Additional educational activities offered by RMEI Medical Education, LLC can be found
at or by calling toll-free (866) 770-RMEI.